Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,089 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02261298 | ONO-4538 Phase I Study in Patients With Solid Tumor | completed | Phase 1 | 18 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT02517398 | MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors | completed | Phase 1 | 600 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | May 3, 2024 | clinicaltrials |
| NCT03005782 |
| Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers |
| completed |
| Phase 1 |
| 333 |
| Regeneron PharmaceuticalsINDUSTRY |
| 5 |
| May 1, 2024 |
| clinicaltrials |
| NCT01898156 | Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer | terminated | Phase 1 / Phase 2 | 37 | Kyowa Kirin Korea Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02516553 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | completed | Phase 1 | 174 | Boehringer IngelheimINDUSTRY | 6 | Apr 15, 2024 | clinicaltrials |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 146 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 12, 2024 | clinicaltrials |
| NCT04557306 | Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer | completed | Phase 1 | 6 | CHABiotech CO., LtdINDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT06344715 | Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. | unknown | Phase 1 | 78 | SL VAXiGENINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT04901806 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | terminated | Phase 1 | 29 | Pyramid BiosciencesINDUSTRY | 11 | Mar 28, 2024 | clinicaltrials |
| NCT05321147 | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 | completed | Phase 1 | 20 | Innate PharmaINDUSTRY | 2 | Mar 28, 2024 | clinicaltrials |
| NCT06326502 | A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Etnova Therapeutics Corp.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 70 | Kartos Therapeutics, Inc.INDUSTRY | 12 | Mar 22, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02081378 | A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | completed | Phase 1 | 326 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 18, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT05783570 | To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 | unknown | Phase 1 | 12 | EutilexINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05231746 | A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001) | completed | Phase 1 | 47 | STCube, Inc.INDUSTRY | 2 | Mar 13, 2024 | clinicaltrials |
| NCT05547906 | Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | MetaFinesINDUSTRY | 2 | Mar 13, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04144140 | Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | terminated | Phase 1 | 24 | Eisai Inc.INDUSTRY | 5 | Mar 7, 2024 | clinicaltrials |
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | completed | Phase 1 / Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 5, 2024 | clinicaltrials |
| NCT03752723 | Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) | completed | Phase 1 / Phase 2 | 84 | Genexine, Inc.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT03720366 | A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients | completed | Phase 1 | 40 | CelgeneINDUSTRY | 2 | Feb 28, 2024 | clinicaltrials |
| NCT03751761 | GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study | completed | Phase 1 / Phase 2 | 58 | Asan Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05971862 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Oscotec Inc.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05248074 | To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers | completed | Phase 1 | 25 | Abion IncINDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT02841540 | A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes(Encore-MDS) | terminated | Phase 1 | 127 | Hemavant Sciences GmbHINDUSTRY | 7 | Feb 14, 2024 | clinicaltrials |
| NCT03639194 | A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 132 | AbbVieINDUSTRY | 4 | Feb 9, 2024 | clinicaltrials |
| NCT05358379 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Feb 7, 2024 | clinicaltrials |
| NCT02789345 | A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer | completed | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 5 | Feb 5, 2024 | clinicaltrials |
| NCT04857138 | A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 80 | Hoffmann-La RocheINDUSTRY | 5 | Feb 5, 2024 | clinicaltrials |
| NCT06014853 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects | completed | Phase 1 | 48 | Bukwang PharmaceuticalINDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04862767 | TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor | completed | Phase 1 | 9 | AutotelicbioINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT02163733 | Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 | 38 | AstraZenecaINDUSTRY | 4 | Jan 22, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT03383692 | Study of DS-8201a for Participants With Advanced Solid Malignant Tumors | completed | Phase 1 | 40 | Daiichi Sankyo Co., Ltd.INDUSTRY | 3 | Dec 11, 2023 | clinicaltrials |
| NCT02608268 | Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 252 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 6, 2023 | clinicaltrials |
| NCT03618758 | Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6(IPLUS) | completed | Phase 1 / Phase 2 | 35 | Seoul National University Bundang HospitalOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02923947 | Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 3 | Nov 27, 2023 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT03684811 | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | completed | Phase 1 / Phase 2 | 93 | Forma Therapeutics, Inc.INDUSTRY | 6 | Nov 18, 2023 | clinicaltrials |
| NCT02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors(CheckMate358) | completed | Phase 1 / Phase 2 | 578 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 128 | H3 Biomedicine Inc.INDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT05400915 | Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients | completed | Phase 1 / Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Nov 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials